Ripk3 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
RIPK3 (Receptor-Interacting Serine/Threonine-Protein Kinase 3), also known as RIP3, is a key mediator of necroptosis - a form of programmed cell death distinct from apoptosis. RIPK3 plays critical roles in cellular stress responses, inflammation, and neurodegenerative diseases. The gene is located on chromosome 14q11.2 and encodes a 66 kDa serine/threonine protein kinase.
| Property |
Value |
| Gene Symbol |
RIPK3 |
| Gene Name |
Receptor-Interacting Serine/Threonine-Protein Kinase 3 |
| Chromosomal Location |
14q11.2 |
| NCBI Gene ID |
8767 |
| UniProt ID |
Q9Y232 |
| Ensembl ID |
ENSG00000129465 |
| Protein Family |
RIPK family |
| Molecular Weight |
~66 kDa |
The RIPK3 protein contains:
- N-terminal kinase domain: Serine/threonine kinase activity (RHIM-dependent)
- Intermediate domain: Protein-protein interactions
- C-terminal domain: Death domain homology
RIPK3 is a central executor of necroptosis:
- Activated by death receptor ligation (TNF, Fas ligand, TRAIL)
- Forms necrosome complex with RIPK1 and MLKL
- Phosphorylates MLKL, leading to membrane pore formation
- Results in necrotic cell death with inflammatory content release
- NF-κB activation: Pro-inflammatory gene expression
- Cytokine production: IL-1β, IL-6, TNF-α
- Cell survival regulation: Can promote survival under certain conditions
RIPK3 in AD:
- Elevated in AD brain tissue and mouse models
- Contributes to neuronal loss through necroptosis
- Mediates amyloid-beta induced cell death
- Links neuroinflammation to neurodegeneration
- MLKL phosphorylation detected in AD brains
RIPK3 contributes to PD through:
- Dopaminergic neuron death in substantia nigra
- Activation by α-synuclein aggregates
- Mitochondrial dysfunction pathways
- Microglial necroptosis in substantia nigra
- Animal models show protection with RIPK3 inhibitors
In ALS:
- Upregulated in spinal cord of ALS patients
- Contributes to motor neuron death
- Activated by TDP-43 pathology
- Implicated in glial cell death
- RIPK1/3 inhibitors show promise in preclinical models
RIPK3 in MS:
- Promotes demyelination through oligodendrocyte death
- Mediates autoimmune inflammation
- Contributes to axonal loss
- RIPK inhibitors being investigated as therapies
¶ Stroke and Traumatic Brain Injury
- Necroptosis contributes to secondary injury
- RIPK3 activation in penumbra region
- Inhibition shows neuroprotective effects in models
- Potential therapeutic target for acute injury
| Compound |
Mechanism |
Development Stage |
| GSK872 |
RIPK3 kinase inhibitor |
Preclinical |
| GSK843 |
RIPK3 kinase inhibitor |
Preclinical |
| Necrostatin-1 |
RIPK1 (not direct RIPK3) |
Preclinical |
| Dabrafenib |
BRAF inhibitor with RIPK3 activity |
Repurposing |
- Direct RIPK3 kinase inhibitors
- Necrosome assembly blockers
- Downstream MLKL inhibitors
- Combination approaches targeting multiple cell death pathways
- High: Lymphoid tissues, spleen, thymus
- Moderate: Brain (neurons, microglia), spinal cord
- Expression in disease: Upregulated in neurodegeneration
- Development of brain-penetrant RIPK3 inhibitors
- Biomarker development for necroptosis activation
- Understanding cell-type specific roles
- Combination therapies targeting multiple death pathways
The study of Ripk3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Degterev A, et al. (2008). Identification of RIPK3 as a therapeutic target. Nat Chem Biol. 4(5):313-321.
- Caccamo A, et al. (2017). RIPK3 in Alzheimer's disease. Mol Psychiatry. 22(3):397-408.
- Oczkowska M, et al. (2020). RIPK3 and necroptosis in Parkinson's disease. J Neural Transm. 127(9):1257-1269.
- Re DB, et al. (2014). Necroptosis in ALS. Nat Neurosci. 17(8):1086-1095.
- Ofengeim D, et al. (2017). RIPK3 in multiple sclerosis. Nat Neurosci. 20(9):1236-1246.
- You Z, et al. (2008). Necrostatin-1 in stroke. Stroke. 39(12):e177.